Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 4INDUSTRY 3FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 5Other hematologic neoplasm 5Thoracic 4Lymphoid 3Gastrointestinal 3Tumor-Agnostic 2Sarcoma 2Plasma cell 2Head & Neck 2Genitourinary 2Dermatologic 2Breast 2Gynecologic 1CNS 1

Conditions

Leukemia, B-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Tablets × Lymphoid × Clear all
NCT00748189 2019-06-25

COMPLEMENT 1

Novartis

Phase 3 Terminated
447 enrolled 32 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01563055 2015-08-10

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

GlaxoSmithKline

Phase 2 Completed
10 enrolled 52 charts
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT01697020 2013-12-02

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Nova Laboratories Limited

Phase 1 Completed
70 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡